What is the difference between Argireline and Sigumir?

Argireline: Inhibits SNARE complex formation in facial muscles; reduces acetylcholine release locally; relaxes expression lines without systemic effects Sigumir: Tetrapeptide bioregulator targeting joint and bone tissue; modulates osteoblast and chondrocyte activity; reduces local joint inflammation; promotes extracellular matrix production

Is Argireline FDA approved?

Argireline is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

Is Sigumir FDA approved?

Sigumir is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is Argireline administered in research settings?

In research settings, Argireline is typically administered via the topical route. PeptideBase does not provide dosing or administration instructions.

How is Sigumir administered in research settings?

In research settings, Sigumir is typically administered via the subcutaneous or oral routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Argireline vs Sigumir

Peptide Comparison

Argireline vs Sigumir

Both are Skin & Cosmetic peptides.

Argireline

Acetyl Hexapeptide-3

Skin & JointNot EvaluatedResearch Only

Half-life: N/A (topical)

18 providers listed

Full Argireline profile →

Sigumir

Val-Glu-Pro-Arg

Skin & JointNot EvaluatedResearch Only

Half-life: Unknown

1 providers listed

Full Sigumir profile →

Bottom line

Argireline carries stronger published evidence (RCT, 3 key studies) than Sigumir (Review, 2); both are research compounds.

Quick Verdict

Argireline

Evidence

Clinical

Sigumir

Evidence

Review-level

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Argireline
Oral administration option	Sigumir
More provider options (18 vs 1)	Argireline

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Argireline

Sigumir

Mechanism Family

Skin & Cosmetic

Half-life

N/A (topical)

Unknown

FDA Status

not evaluated

Admin Routes

topical

subcutaneous, oral

Availability

Research Only

Providers

18 listed

1 listed

Avail. Notes

Cosmetic peptide (acetyl hexapeptide-3). Sold as cosmetic ingredient by Lipotec/Sederma. Not regulated as a drug by FDA. No NDA or IND. Cosmetic anti-wrinkle ingredient only.

Russian joint peptide bioregulator (Khavinson Institute). Not FDA-approved. Not on any FDA list. Research chemical in US.

Research Evidence

Argireline

ClinicalRCT · 3 key studies · most recent 2026

Sigumir

Review-levelReview · 2 key studies · most recent 2023

Research Citations

Argireline

RCT2013 · American Journal of Clinical Dermatology

The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-…

Cohort2026 · Biomater Adv

DES-mediated self-assembled polypeptides: Synergistic neuromuscular signaling inhibition for anti-aging.

RCT2017 · Journal of Cosmetic Dermatology

The efficacy study of the combination of tripeptide-10-citrulline and acetyl hexapeptide-3: a prospective, ra…

Sigumir

Review2023 · Biomolecules

Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters

Review2021 · Molecules

Peptide Regulation of Gene Expression: A Systematic Review

About Argireline

Inhibits SNARE complex formation in facial muscles; reduces acetylcholine release locally; relaxes expression lines without systemic effects

Research Areas

SNARE complex (SNAP-25) competitive inhibition reducing expression line depthwrinkle reduction documented in controlled human trialstopical cosmetic application — not a systemic peptidesoftening of dynamic lines over 4–8 weeks at 5–10% concentration

About Sigumir

Tetrapeptide bioregulator targeting joint and bone tissue; modulates osteoblast and chondrocyte activity; reduces local joint inflammation; promotes extracellular matrix production

Research Areas

joint tissue repairbone and cartilage supportanti-inflammatory (joint)mobility improvement

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Argireline

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Sigumir

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Find Providers

Where to source these peptides

Providers offering

Argireline

18 listed

Browse directory →

Providers offering

Sigumir

1 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Skin & Cosmetic Comparisons

Browse all peptides →

Educational research tools — not medical advice.